Study Links GLP-1 Drugs to 48% Higher Smell and Taste Risk

Q: Ozempic can alter your taste and smell. Is this change permanent?

Probably not in most cases, but it is not yet known whether Ozempic-related taste or smell changes can ever be permanent. The new Hebrew University study found a small increased risk of diagnosed smell and taste disturbances among GLP-1 users, including semaglutide. But it was an observational review of medical records, so it cannot prove the drug caused the problem, and it did not establish how long symptoms lasted. What is known is that the absolute risk was low: about 0.37% of GLP-1 users versus 0.22% of comparable patients on other diabetes drugs. Researchers say the drugs may affect GLP-1 receptors in taste buds and the olfactory bulb, which could help explain the link. There is also some reason to think these changes may be reversible for at least some patients. Experts cited in the reporting say early recognition matters because interventions such as olfactory training can help people recover smell and taste function. More broadly, many GLP-1 side effects tend to improve as the body adjusts, though that has not been definitively proven for these sensory symptoms. The bottom line is that permanence has not been established. If you notice dulled taste, distorted flavors, reduced smell, or food suddenly seeming unpleasant after starting Ozempic, tell your clinician. Persistent symptoms, especially beyond several weeks or a few months, deserve medical review to rule out other causes and discuss whether treatment changes or smell training may help.

2 articles · Updated · Healthline · Jun 25

769 GLP-1 users developed taste disturbances and 649 reported smell problems, versus 445 and 316 in a matched non-GLP-1 diabetes group, according to a new observational study.
More than 430,000 adults were included in each cohort from the TriNetX network, and researchers said the drugs may affect olfactory and chemosensory pathways through the nervous system.
0.37% of GLP-1 users had smell or taste issues compared with 0.22% of non-users, suggesting the side effect is uncommon even though risk was higher.
Doctors not involved in the study said they have not seen major patient concern, stressed the research does not prove causation, and said the weight-loss and diabetes benefits still likely outweigh the sensory risks.